AC Immune (ACIU) Rating Lowered to Buy at BidaskClub

BidaskClub cut shares of AC Immune (NASDAQ:ACIU) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday morning.

A number of other equities analysts have also recently commented on ACIU. Zacks Investment Research cut AC Immune from a buy rating to a hold rating in a report on Tuesday, October 9th. Leerink Swann started coverage on AC Immune in a report on Monday, November 12th. They issued an outperform rating and a $18.00 target price for the company. UBS Group started coverage on AC Immune in a report on Friday, January 4th. They issued a buy rating and a $16.00 target price for the company. Finally, HC Wainwright reiterated a buy rating and issued a $18.00 target price on shares of AC Immune in a report on Thursday, January 24th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. AC Immune has a consensus rating of Hold and an average target price of $13.80.

Shares of AC Immune stock opened at $3.92 on Tuesday. The company has a market capitalization of $261.48 million, a PE ratio of -13.07 and a beta of -0.09. AC Immune has a one year low of $3.25 and a one year high of $17.40.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Tuesday, November 13th. The company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.04. The firm had revenue of $2.34 million during the quarter, compared to analysts’ expectations of $1.71 million. AC Immune had a negative return on equity of 24.14% and a negative net margin of 146.09%. As a group, research analysts forecast that AC Immune will post -0.42 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in AC Immune during the 3rd quarter valued at $107,000. GSA Capital Partners LLP purchased a new stake in shares of AC Immune in the 3rd quarter worth $110,000. JPMorgan Chase & Co. purchased a new stake in shares of AC Immune in the 3rd quarter worth $142,000. Compagnie Lombard Odier SCmA lifted its holdings in shares of AC Immune by 858.3% in the 3rd quarter. Compagnie Lombard Odier SCmA now owns 33,539 shares of the company’s stock worth $268,000 after buying an additional 30,039 shares during the period. Finally, Belpointe Asset Management LLC purchased a new stake in shares of AC Immune in the 3rd quarter worth $400,000. Institutional investors own 29.06% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Story: Why do companies engage in swaps?

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply